Chimerix News

Buy Rating Justified by Chimerix's Upcoming Catalysts and Strong Financials

TipRanksMay 3 15:05 ET

Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 2 10:23 ET

Strong Buy Rating for Chimerix on Robust Financials and Promising Drug Pipeline

TipRanksMay 2 06:30 ET

Chimerix Inc (CMRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...

Yahoo FinanceMay 2 03:09 ET

Chimerix's Strong Financials and Promising ONC201 Developments Merit Buy Rating

TipRanksMay 1 18:35 ET

Earnings Call Summary | Chimerix(CMRX.US) Q1 2024 Earnings Conference

The following is a summary of the Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript:Financial Performance:The balance sheet at the end of March 2024 reported a $188.2 million available capital wi

moomoo AIMay 1 12:15 ET · Conference Call

Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript

Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 1 11:28 ET

Chimerix Releases Updated Corporate Presentation for Investors

TipRanksMay 1 08:33 ET

Express News | Corrected-Chimerix Q1 Net Income USD -21.9 Million (Corrects Amount)

ReutersMay 1 08:12 ET

Express News | Chimerix Expects Dordaviprone Interim Overall Survival Data In 2025 And Final OS Data In 2026

BenzingaMay 1 07:13 ET

Express News | Chimerix Q1 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate

BenzingaMay 1 07:06 ET

Express News | Chimerix Inc - Qtrly Net Loss of $21.9 Mln, or $0.25 per Basic and Diluted Share

ReutersMay 1 07:04 ET

Express News | Chimerix Q1 Net Income USD -250

ReutersMay 1 07:00 ET

Chimerix 1Q Rev $0.00 >CMRX

Chimerix 1Q Rev $0.00 >CMRX

Dow JonesMay 1 07:00 ET

Press Release: Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update -- Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data

Dow JonesMay 1 07:00 ET

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studi

ChimerixMay 1 00:00 ET

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients

ChimerixApr 24 00:00 ET

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards

ChimerixApr 16 00:00 ET

We Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth Carefully

Yahoo FinanceApr 15 06:17 ET

Express News | WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC Alone, More Than 4500 Cases of #mpox and Almost 300 Deaths Have Been Reported This Year. That Is Triple the Number Reported at This Time Last Year. The Recent Surge in Cases and Deaths Among Children Is

Moomoo 24/7Apr 11 10:09 ET